Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 8;61(6):2300614.
doi: 10.1183/13993003.00614-2023. Print 2023 Jun.

Combining rituximab with mycophenolate for the treatment of interstitial lung disease

Elizabeth R Volkmann  1
Affiliations
Editorial

Combining rituximab with mycophenolate for the treatment of interstitial lung disease

Elizabeth R Volkmann. Eur Respir J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: E.R. Volkmann is supported by the National Heart, Lung, and Blood Institute (grant number K23 HL150237) and reports the following financial relationships outside of the submitted work on autoimmune-associated ILD: consulting for Boehringer Ingelheim, Roche, CSL Behring and GSK, speaking for Boehringer Ingelheim, and institutional support received for performing studies in systemic sclerosis for Kadmon, Forbius, Boehringer Ingelheim, Horizon and Prometheus.

Comment on

References

    1. Hambly N, Farooqi MM, Dvorkin-Gheva A, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J 2022;60:2102571. - PubMed
    1. Jeganathan N, Sathananthan M. The prevalence and burden of interstitial lung diseases in the USA. ERJ Open Res 2021;8:00630–2021. - PMC - PubMed
    1. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022;205:e18–e47. - PMC - PubMed
    1. Mankikian J, Caille A, Reynaud-Gaubert M, et al. Rituximab and mycophenolate mofetil combination in patients with interstitital lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J 2023. - PubMed
    1. Tashkin DP, Roth MD, Clements PJ, et al.; Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708–719. - PMC - PubMed

MeSH terms